|By PR Newswire||
|March 5, 2014 07:00 AM EST||
HONOLULU, March 5, 2014 /PRNewswire/ -- The Department of Defense, Defense Threat Reduction Agency, has awarded Hawaii Biotech, Inc., a contract to continue developing drugs to block botulinum toxin, the toxin that causes the life-threatening disease, botulism. There is no therapeutic drug currently available for the treatment of botulism.
The award has a first-year period of performance through early 2014, followed by three option years with a total contract value of approximately $5.5 million.
"This contract, in addition to the $7.4 million grant for an anti-anthrax drug, demonstrates the confidence that Federal agencies have in Hawaii Biotech's ability to develop these drug candidates, as well as our historic commitment to vaccines for tropical and emerging diseases such as West Nile Virus," said Dr. Elliot Parks, CEO of Hawaii Biotech. "Hawaii Biotech is now fully engaged in the development of therapeutic drugs to combat infectious diseases that pose potential bioterrorism threats, as well as continuing development of vaccines for infectious agents."
Under the contract, Hawaii Biotech will be working to improve its current anti-botulinum toxin inhibitor drug candidates that have demonstrated activity in pre-clinical testing. The goal will be to enhance the stability, bioavailability and safety of these drug candidates so they can be used in humans.
"We look forward to continuing the productive relationship with the Defense Threat Reduction Agency and Hawaii Biotech's team to develop countermeasures to bioterrorism threats," said Dr. Sean O'Malley, the principal investigator.
About Hawaii Biotech, Inc. (HBI):
Hawaii Biotech is a privately held biotechnology company focused on the development of prophylactic vaccines for established and emerging infectious diseases and anti-toxin drugs for biological threats. HBI has developed proprietary expertise in the production of recombinant proteins that have application to the manufacture of safe and effective vaccines, diagnostic kits and as research tools. HBI completed successful first-in-human Phase 1 clinical studies with both West Nile virus and dengue vaccines in healthy human subjects. HBI is currently engaged in the development of a product pipeline of recombinant subunit vaccines, including vaccine candidates for West Nile virus, tick-borne flavivirus, malaria, Crimean-Congo hemorrhagic fever and discovery of small molecule anti-toxin drugs for anthrax and botulism. HBI, founded in Hawaii in 1982, is headquartered in suburban Honolulu. For more information, please visit: www.hibiotech.com.
About Botulinum Toxin:
Botulinum toxin affects nerve-muscle junctions, preventing the release of neurotransmitters and causing flaccid paralysis. Naturally occurring intoxication can occur through ingestion of contaminated foods, colonization of the gut (infant botulism), or through a wound. While small amounts can be used for beneficial medical purposes (e.g., Botox®), larger quantities of the readily prepared toxin can be used for nefarious purposes. Production of the toxin for weaponization by several countries and terrorist organizations has been documented. Therefore botulinum toxin is one of the most significant bioterror concerns, listed as a Category A biodefense threat agent by the Centers for Disease Control and Prevention. Poisoning food supplies could lead to a mass casualty event causing paralysis and death through respiratory failure in large numbers of victims. Battlefield use of a botulinum toxin aerosol could incapacitate and kill warfighters and support personnel. Terrorist use could lead to casualties in civilians and first responders. For more information, please visit: http://emergency.cdc.gov/agent/botulism/
SOURCE Hawaii Biotech, Inc.
"AgilData is the next generation of dbShards. It just adds a whole bunch more functionality to improve the developer experience," noted Dan Lynn, CEO of AgilData, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 6, 2015 09:00 AM EDT Reads: 1,321
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading in...
Jul. 6, 2015 09:00 AM EDT Reads: 412
SYS-CON Events announced today that Cloudian, Inc., the leading provider of hybrid cloud storage solutions, will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Cloudian, Inc., is a Foster City, California - based software company specializing in cloud storage software. The main product is Cloudian, an Amazon S3-compliant cloud object storage platform, the bedrock of cloud computing system...
Jul. 6, 2015 09:00 AM EDT Reads: 1,976
Containers are revolutionizing the way we deploy and maintain our infrastructures, but monitoring and troubleshooting in a containerized environment can still be painful and impractical. Understanding even basic resource usage is difficult – let alone tracking network connections or malicious activity. In his session at DevOps Summit, Gianluca Borello, Sr. Software Engineer at Sysdig, will cover the current state of the art for container monitoring and visibility, including pros / cons and liv...
Jul. 6, 2015 09:00 AM EDT Reads: 1,722
Jul. 6, 2015 08:45 AM EDT Reads: 1,774
"We have a tagline - "Power in the API Economy." What that means is everything that is built in applications and connected applications is done through APIs," explained Roberto Medrano, Executive Vice President at Akana, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 6, 2015 08:45 AM EDT Reads: 1,648
WebRTC converts the entire network into a ubiquitous communications cloud thereby connecting anytime, anywhere through any point. In his session at WebRTC Summit,, Mark Castleman, EIR at Bell Labs and Head of Future X Labs, will discuss how the transformational nature of communications is achieved through the democratizing force of WebRTC. WebRTC is doing for voice what HTML did for web content.
Jul. 6, 2015 08:15 AM EDT Reads: 1,513
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction. Th...
Jul. 6, 2015 08:00 AM EDT Reads: 1,554
Jul. 6, 2015 07:30 AM EDT Reads: 1,551
Jul. 6, 2015 07:15 AM EDT Reads: 1,597
Jul. 6, 2015 05:30 AM EDT Reads: 2,241
Jul. 6, 2015 05:00 AM EDT Reads: 1,558
Jul. 6, 2015 03:00 AM EDT Reads: 2,448
Jul. 6, 2015 02:45 AM EDT Reads: 2,766
Jul. 5, 2015 08:00 PM EDT Reads: 1,680